<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLINDACIN P- clindamycin phosphate swab </strong><br><strong>CLINDACIN PAC- clindamycin phosphate swab </strong><br>Medimetriks Pharmaceuticals, Inc.<br></p></div>
<h1>Clindamycin Phosphate Topical Solution, USP<br> Pledgets 1%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold Italics">R<span class="Sub">x</span> Only</span></p>
<p><span class="Bold">For External Use</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">Clindacin•P</span>™ contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter.</p>
<p>Each<span class="Bold"> Clindacin•P</span>™ pledget applicator contains approximately 1 mL of topical solution.</p>
<p>Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.</p>
<p>The solution contains isopropyl alcohol 50% v/v, propylene glycol, purified water, and sodium hydroxide (to adjust the pH to between 4.0 - 7.0). The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288371ef-96b6-4ce3-9be1-1d9d309b400c&amp;name=clindacin-01.jpg"></div>
<p>The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-α-D-<span class="Italics">galacto</span>-octopyranoside 2-(dihydrogen phosphate).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Although clindamycin phosphate is inactive<span class="Italics"> in vitro</span>, rapid<span class="Italics"> in vivo </span>hydrolysis converts this compound to the antibacterially active clindamycin.</p>
<p>Cross resistance has been demonstrated between clindamycin and lincomycin. Antagonism has been demonstrated between clindamycin and erythromycin.</p>
<p>Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.</p>
<p>Clindamycin activity has been demonstrated in comedones from <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients. The mean concentration of antibiotic activity in extracted comedones after application of clindamycin phosphate topical solution for 4 weeks was 597 mcg/g of comedonal material (range 0–1490). Clindamycin<span class="Italics"> in vitro </span>inhibits all<span class="Italics"> Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span> </span>cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Clindacin•P</span>™ is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. In view of the potential for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, the physician should consider whether other agents are more appropriate (see<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#WARNINGS"> WARNINGS </a></span>and<span class="Bold"><a href="#AR"> ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">Clindacin•P</span>™ is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to preparations containing clindamycin or lincomycin, a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may result in patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of topical and systemic clindamycin.</span></p>
<p><span class="Bold">Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is usually characterized by severe persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and may be associated with the passage of blood and mucus. Endoscopic examination may reveal <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. <span class="Underline">Stool culture for<span class="Italics"> Clostridium difficile </span>and stool assay for<span class="Italics"> C. difficile </span>toxin may be helpful diagnostically.</span></span></p>
<p><span class="Bold">When significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</span></p>
<p><span class="Bold">Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> produced by<span class="Italics"> Clostridium difficile</span>. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. <span class="Underline">Cholestyramine or colestipol resins bind vancomycin<span class="Italics"> in vitro</span>.</span> If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold">Clindacin•P</span>™ contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth. Clindamycin phosphate topical products should be prescribed with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.3"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.3.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 100 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether clindamycin is excreted in human milk following use of<span class="Bold"> Clindacin•P</span>™. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients under the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies for clindamycin phosphate topical solution USP, 1% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].</p>
<table width="75%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="6">Number of Patients Reporting Events</th>
</tr>
<tr class="Last">
<th align="left">Treatment Emergent<br>Adverse Event</th>
<th align="left" colspan="2">Solution<br>n=553 (%)</th>
<th align="left" colspan="2">Gel<br>n=148 (%)</th>
<th align="left" colspan="2">Lotion<br>n=160 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>not recorded</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>of 126 subjects</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Burning</td>
<td align="left">  62</td>
<td align="left">  (11)</td>
<td align="left">15</td>
<td align="left">(10)</td>
<td align="left">17</td>
<td align="left">(11)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td align="left">  36</td>
<td align="left">  (7)</td>
<td align="left">15</td>
<td align="left">(10)</td>
<td align="left">17</td>
<td align="left">(11)</td>
</tr>
<tr>
<td align="left">Burning/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td align="left">  60</td>
<td align="left">  (11)</td>
<td align="left"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></td>
<td align="left">( – )</td>
<td align="left"><a href="#footnote-1" class="Sup">*</a></td>
<td align="left">( – )</td>
</tr>
<tr>
<td align="left">Dryness</td>
<td align="left">105</td>
<td align="left">  (19)</td>
<td align="left">34</td>
<td align="left">(23)</td>
<td align="left">29</td>
<td align="left">(18)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td align="left">  86</td>
<td align="left">  (16)</td>
<td align="left">10</td>
<td align="left">(7)</td>
<td align="left">22</td>
<td align="left">(14)</td>
</tr>
<tr>
<td align="left">Oiliness/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Oily Skin</span></td>
<td align="left">    8</td>
<td align="left">  (1)</td>
<td align="left">26</td>
<td align="left">(18)</td>
<td align="left">12<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="left">(10)</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Peeling</span></td>
<td align="left">  61</td>
<td align="left">  (11)</td>
<td align="left"><a href="#footnote-1" class="Sup">*</a></td>
<td align="left">( – )</td>
<td align="left">11</td>
<td align="left">(7)</td>
</tr>
</tbody>
</table>
<p>Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may end fatally.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> as well as gram-negative <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span> have also been reported in association with the use of topical formulations of clindamycin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied<span class="Bold"> Clindacin•P</span>™ can be absorbed in sufficient amounts to produce systemic effects (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Clindacin•P</span>™ (Clindamycin Phosphate Topical Solution, USP Pledget 1%) is available as follows:</p>
<p>A jar containing 69 single-use pledget applicators (NDC 43538-170-69)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from freezing.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured for Medimetriks Pharmaceuticals, Inc.<br>363 Route 46 West, Fairfield, NJ 07004-2402 • www.medimetriks.com</p>
<p>Manufactured by PERRIGO<br>Bronx, NY 10457</p>
<p>Rev. Date: 12/10</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 69 Pledget Carton</h1>
<p class="First">NDC 43538-170-69</p>
<p><span class="Bold">For Topical Use Only</span></p>
<p><span class="Bold Italics">R<span class="Sub">x</span> Only</span></p>
<p><span class="Bold Italics">Clindacin•P™</span></p>
<p>Clindamycin Phosphate<br>Topical Solution, USP Pledget 1%*</p>
<p>*equivalent to 1% (10 mg/mL) clindamycin</p>
<p><span class="Bold">MEDIMETRIKS<br>PHARMACEUTICALS, INC.</span></p>
<p><span class="Italics">69 Pledgets</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 69 Pledget Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288371ef-96b6-4ce3-9be1-1d9d309b400c&amp;name=clindacin-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 69 Pledget Kit</h1>
<p class="First">NDC 43538-171-69</p>
<p><span class="Italics">R<span class="Sub">x</span> Only</span></p>
<p><span class="Bold Italics">Clindacin™ pac</span></p>
<p>Clindamycin Phosphate<br>Topical Solution, USP Pledget 1%*</p>
<p>*equivalent to 1% (10 mg/mL) clindamycin</p>
<p><span class="Bold">MEDIMETRIKS<br>PHARMACEUTICALS, INC.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 69 Pledget Kit" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288371ef-96b6-4ce3-9be1-1d9d309b400c&amp;name=clindacin-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDACIN P 		
					</strong><br><span class="contentTableReg">clindamycin phosphate swab</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43538-170</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>clindamycin phosphate</strong> (clindamycin) </td>
<td class="formItem">clindamycin</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43538-170-69</td>
<td class="formItem">69  in 1 JAR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065049</td>
<td class="formItem">02/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDACIN PAC 		
					</strong><br><span class="contentTableReg">clindamycin phosphate swab</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43538-171</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>clindamycin phosphate</strong> (clindamycin) </td>
<td class="formItem">clindamycin</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43538-171-69</td>
<td class="formItem">1  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">69  in 1 JAR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065049</td>
<td class="formItem">02/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Medimetriks Pharmaceuticals, Inc.
							(019903816)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Perrigo Inc.</td>
<td class="formItem"></td>
<td class="formItem">078846912</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>14589970-0f9f-46c6-8c65-a64041b80e7c</div>
<div>Set id: 288371ef-96b6-4ce3-9be1-1d9d309b400c</div>
<div>Version: 1</div>
<div>Effective Time: 20110214</div>
</div>
</div> <div class="DistributorName">Medimetriks Pharmaceuticals, Inc.</div></p>
</body></html>
